Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Abstract

Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. Methods We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or local ablation (n=214) in 202 sites (hospitals and research centres) in 28 countries. Patients were randomly assigned (1:1) to receive 400 mg oral sorafenib or placebo twice a day, for a maximum of 4 years, according to a block randomisation scheme (block size of four) using an interactive voice-response system. Patients were stratified by curative treatment, geography, Child-Pugh status, and recurrence risk. The primary outcome was recurrence-free survival assessed after database cut-off on Nov 29, 2013. We analysed efficacy in the intention-to-treat population and safety in randomly assigned patients receiving at least one study dose. The final analysis is reported. This study is registered with ClinicalTrials.gov, number NCT00692770. Findings We screened 1602 patients between Aug 15, 2008, and Nov 17, 2010, and randomly assigned 1114 patients. Of 556 patients in the sorafenib group, 553 (>99%) received the study treatment and 471 (85%) terminated treatment. Of 558 patients in the placebo group,…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(15)00198-9

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Cited by

See all 1,120

Metadata

Authors
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., Lee, H. C., Song, T., Roayaie, S., Bolondi, L., Lee, K. S., Makuuchi, M., Souza, F., Berre, M.-A. L., Meinhardt, G., & Llovet, J. M.
Affiliations
  • Hospital Clínic de Barcelona (ES)
  • Nihon University (JP)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Taipei Veterans General Hospital (TW)
  • Kindai University (JP)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Queen Mary Hospital (CN)
  • Severance Hospital (KR)
  • Kyungpook National University (KR)
  • Asan Medical Center (KR)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Hofstra University (US)
  • University of Bologna (IT)
  • Gangnam Severance Hospital (KR)
  • The University of Tokyo (JP)
  • Bayer (United States) (US)
  • Mount Sinai Hospital (US)
Corresponding author
Bruix, Jordi
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-10
Volume
16
Issue
13
Pages
1344-1354
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2115991409
Cited by
1,120
References
39
Citations by year
2026: 64 · 2025: 98 · 2024: 117 · 2023: 116 · 2022: 108 · 2021: 112 · 2020: 116 · 2019: 97 · 2018: 98 · 2017: 106 · 2016: 68 · 2015: 17
FWCI
57.10
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Funders
  • Bayer Fund
  • Bayer HealthCare
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
hepatocellular carcinoma, sorafenib, adjuvant therapy, hepatectomy, local ablation, recurrence-free survival, recurrence, tyrosine kinase inhibitors, treatment safety, dose adjustment, recurrence risk stratification, radiological response, dose-limiting toxicity
MeSH terms
Sorafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Asia, Australia, Double-Blind Method, Europe, Female, Hepatectomy, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, New Zealand, Niacinamide, North America, Phenylurea Compounds, Risk Factors, South America, Time Factors, Treatment Outcome, Chemotherapy, Adjuvant, Catheter Ablation, Disease Progression, Disease-Free Survival, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(15)00198-9
The paper
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., Lee, H. C., Song, T., Roayaie, S., Bolondi, L., Lee, K. S., Makuuchi, M., Souza, F., Berre, M.-A. L., Meinhardt, G., & Llovet, J. M. (2015). Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00198-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.